The case for investing in provider-administered subcutaneous DMPA: a costing study
Not all DMPA-SC users need to self-inject for DMPA-SC to be cost-competitive with DMPA-IM. Use of PA DMPA-SC may increase the uptake of SI over time.
Authors
- Jessie Salamba Chirwa
- Rick Homan (ORCID: https://orcid.org/0000-0001-9827-9238)
- Mario Chen (ORCID: https://orcid.org/0000-0002-2434-2182)
- Megan Lydon
- Holly M. Burke (ORCID: https://orcid.org/0000-0002-5538-5628)
- Wingston Ng’ambi
- Hannah Kachule
- Grace Jabu
Institutions
- Family Health International 360 (US)
- Statistics Korea (KR)
- Malawi Government (MW)
- Ministry of Health (MW)
Publication Details
- Journal
- BMJ Global Health
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/bmjgh-2024-018761
- Citations
- 1
- Primary Topic
- Patient Satisfaction in Healthcare
- Type
- article
- Field-Weighted Citation Impact
- 2.82
Funders
- Bill and Melinda Gates Foundation
- Children's Investment Fund Foundation